Since 1970, medac has stood for...
... treading new paths.

Year of foundation

Start of specialisation in oncology

Establishment of the branch office in Vienna, Austria

Establishment of the branch office in Uk

Establishment of the branch office in Prague, Czech Republic


  • Schering AG, Berlin, buys a 25% share in the company
  • medac acquires the German distribution rights for fludarabine phosphate and cyproterone acetate in the field of oncology

Schering AG, Berlin, licenses aminolevulinic acid for the diagnosis of superficial bladder cancer in the majority of countries in Europe


  • Relocation from Hamburg city centre to the company’s own building in Wedel, Schleswig Holstein
  • Establishment of medac Scandinavia, with headquarters in Varberg, Sweden
  • Establishment of Oncotec GmbH as a manufacturer of cytostatic drugs in Tornau, Dessau, Germany
  • Establishment of ProThera GmbH for the genetically engineered production of recombinant proteins in Jena, Germany


  • Establishment of photonamic GmbH & Co KG as a new subsidiary of medac for the research areas of fluorescence diagnostics and photodynamic therapies
  • since 7.3.2002, research reagents and IVDs can also be ordered on the internet
  • Establishment of medac Polska, with headquarters in Warsaw

Acquisition of Schering AG’s shares in medac by the original shareholders


  • Establishment of medac Portugal, Lisbon
  • Completion of the 2nd construction phase at Oncotec and immediate start of the 3rd construction phase
  • Launch of the first product developed entirely by medac -  Gliolan - in Europe

Construction of a centre for logistics, quality control and development, manufacture and support of diagnostic agents in Tornesch, Germany

The number of employees rises to more than 1000